Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Psychopharmacology|July 18, 2016
On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderlyAnnemiek Vermeeren, Eva Vets, Eric F P M Vuurman, et al.
Journal of Clinical Pharmacology|December 14, 2007
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlationMarian Iwamoto, Kelem Kassahun, Matthew D Troyer, et al.
Sleep|June 4, 2015
On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy VolunteersAnnemiek Vermeeren, Hong Sun, Eric F P M Vuurman, et al.
Journal of Clinical Psychopharmacology|June 3, 2016
Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover StudyKerri A Schoedel, Hong Sun, Edward M Sellers, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 5, 2015
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's diseaseDaniel Weintraub, Tanya Simuni, Chelsea Caspell-Garcia, et al.
The New England Journal of Medicine|December 30, 2025
An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis IIJoseph Muenzer, Barbara K Burton, Paul Harmatz, et al.
International Journal of Molecular Sciences|July 26, 2020
Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II PatientsAkhil Bhalla, Ritesh Ravi, Meng Fang, et al.
Science Translational Medicine|November 4, 2016
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patientsMatthew E Kennedy, Andrew W Stamford, Xia Chen, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 22, 2023
LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's DiseaseDanna Jennings, Sarah Huntwork-Rodriguez, Maurits F J M Vissers, et al.
Clinical and Translational Science|June 1, 2022
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patientsMaurits F J M Vissers, Jules A A C Heuberger, Geert Jan Groeneveld, et al.
Pageof 9